Dr.Syed Sibtain ul Hassan

25/12/2025

🔵 High Blood Pressure – 6 Common Myths Busted
🔵 CardioSmart – American College of Cardiology

🟢 MYTH 1
🟢 I feel fine, so my blood pressure must be OK.

🟢 FACT 1
🟢 High blood pressure is called the “silent killer” for a reason.
🟢 It often has no symptoms.
🟢 If left untreated, it can cause heart attack, stroke, and kidney failure.
🟢 Get checked.

🟡 MYTH 2
🟡 My blood pressure is only a little high, so it’s no big deal.

🟡 FACT 2
🟡 Even slightly elevated blood pressure can lead over time to heart disease, heart attack, stroke, and dementia.
🟡 Healthy blood pressure is lower than 120/80 mm Hg.
🟡 Get moving to prevent problems.

🟣 MYTH 3
🟣 High blood pressure affects only older people.

🟣 FACT 3
🟣 Blood pressure tends to rise with age, but adults of all ages can develop high blood pressure.
🟣 About 1 in 4 young adults aged 18–39 have high blood pressure.
🟣 Ask about your numbers.

🔵 MYTH 4
🔵 Blood pressure medicines can cause erectile dysfunction (ED).

🔵 FACT 4
🔵 High blood pressure itself can cause erectile dysfunction, which may be an early warning sign of heart disease.
🔵 High blood pressure can also affect women’s sexual health.
🔵 Some medicines such as certain diuretics and beta blockers may increase ED risk, but many do not.
🔵 Discuss concerns before changing medicines.

🟢 MYTH 5
🟢 It’s just a man’s disease.

🟢 FACT 5
🟢 Men can have high blood pressure at younger ages, but women can too.
🟢 Women may develop high blood pressure during pregnancy or shortly afterward.
🟢 High blood pressure affects men and women of all ages.
🟢 Stay on top of your heart health at any age.

🟡 MYTH 6
🟡 Salt is the main culprit for high blood pressure.

🟡 FACT 6
🟡 Salt (sodium) matters, including hidden salt in packaged foods, sauces, and breads.
🟡 Lack of physical activity, excess weight, stress, alcohol, and poor sleep can also raise blood pressure.
🟡 Choose healthy habits.

24/12/2025

Heart 360 | Istanbul 🇹🇷
Advancing cardiometabolic care through updated guidelines, evolving therapies, and real-world clinical insights—shaping the future of heart health.

24/12/2025

23/12/2025

İstinye University, Istanbul 🇹🇷
A beautiful campus enriched with history, where tradition meets modern education in the heart of Istanbul.

23/12/2025

Heart 360 | Istanbul, Turkey
An engaging scientific exchange on updated cardiometabolic guidelines, evolving treatment strategies, and real-world clinical perspectives shaping modern cardiovascular care.
Organized by Hoechst / Sanofi.

20/12/2025

16/12/2025

AASLD

15/12/2025

https://maps.app.goo.gl/AGhbD187oiUpQj38A?g_st=ipc

Find local businesses, view maps and get driving directions in Google Maps.

14/12/2025

✍Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic o***y syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes.
✍This review synthesizes current evidence on pharmacokinetics, safety in preconception and early pregnancy, and clinical management strategies for glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in women of reproductive age. Ethical and health system considerations are also explored to inform clinical practice and highlight future research priorities.
✍A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar identified 132 articles. After screening and full-text review, 9 studies met the inclusion criteria for synthesis.
✍Semaglutide (~7 days) and tirzepatide (~5 days) have long half-lives, requiring discontinuation at least 35 days and 25–35 days, respectively, before conception, while liraglutide requires ≥3 days.
✍Human data show no significant increase in congenital anomalies with inadvertent early exposure, although evidence is limited and observational. Alternatives such as metformin, lifestyle modification, and bariatric surgery remain safer options.
✍GLP-1 RAs may aid preconception metabolic optimization; however, evidence remains limited and largely observational. Preconception discontinuation timed to each agent’s half-life is prudent to minimize potential fetal exposure. Prospective studies and pregnancy registries are needed to confirm reproductive safety and refine guidance.

🤓Very important topic
🤓The use of antiobesity medications in preconception will be increasing further
🤓It is unlikely that we will have randomized trials but more observational data on GLP-1 based therapies we have, the better.
🤓So far, so good, no major reports of effects on congenital anomalies reported.
🤓Nevertheless, the medication should be still discontinued before conception - 2 months before for semaglutide and 1 months before for tirzepatide according to SPCs

13/12/2025

First-in-Class 'Triple-G'!

Retatrutide, a first-in-class GIP, GLP-1 & Glucagon triple hormone receptor agonist drug leads to nearly 29% weight loss in first pivotal test!

Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety & efficacy of Retatrutide, a first-in-class GIP, GLP-1 & glucagon triple hormone receptor agonist, in adults with obesity or overweight & knee osteoarthritis.

The double-blind, placebo-controlled TRIUMPH-4 study included 445 participants (mean baseline body weight: 112.7kg; mean baseline WOMAC pain subscale score: 6.0 points; mean baseline WOMAC physical function subscale score: 5.8 points) who were randomly assigned 1:1:1 to receive either retatrutide 9 mg, retatrutide 12 mg or placebo by subcutaneous injection.

The coprimary endpoints were the percent change from baseline in body weight and the change from baseline in WOMAC pain subscale score at week 68.

Eli Lilly's Retatrutide lowered weight by up to an average of 28.7% in adults with obesity or overweight, the first results from eight ongoing late-stage studies of the 'triple-G' drug.

In the TRIUMPH-4 trial, people on Retatrutide — which targets GIP, GLP-1 and glucagon — also experienced a reduction in knee osteoarthritis pain of up to 75.8%.

Discontinuation rates due to AEs were 12.2% and 18.2% with Retatrutide 9 mg and 12 mg, respectively, compared to 4% with placebo. Lilly explained that the rates were highly correlated with baseline BMI and included discontinuations for perceived excessive weight loss.

12/12/2025

AASLD

12/12/2025

Engaged in a meaningful round-table on Tirzepatide therapy, the global evidence base, and Pakistan’s potential leadership in biosimilar manufacturing to expand high-quality, affordable treatment options.
Collaborative dialogue is essential as we move towards better cardiometabolic outcomes nationwide.